Skip to main content
Erschienen in: Clinical Rheumatology 3/2008

01.03.2008 | Original Article

Assessment of laboratory measurements and −308 TNFα gene promoter polymorphisms in normal bone mineral density

verfasst von: Helena Canhao, Joao Eurico Fonseca, Joana Caetano-Lopes, Carlota Saldanha, Mario Viana Queiroz

Erschienen in: Clinical Rheumatology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to identify and evaluate laboratory parameters associated with normal bone mineral density (BMD) and to test if −308 tumour necrosis factor (TNF) alpha gene promoter polymorphisms could influence BMD. We performed a comparative cross-sectional study of four main groups: young healthy individuals (20–30 years); subjects aged 50 years or over with normal BMD; osteoporotic subjects aged 50 years or over; osteoporotic women with active rheumatoid arthritis. Variables assessed included anthropometric features, diet intake, lifestyle, calcium–phosphorus balance, markers of bone turnover, sexual hormones, hormones related with body mass and growth, cytokines involved in inflammation and bone turnover, and −308 TNF alpha gene promoter polymorphisms. One hundred fifty-nine subjects were evaluated. Across the four groups, zinc serum levels were higher in men as compared to women. In addition, zinc serum levels were also higher in individuals with normal BMD as compared to osteoporotic subjects. Serum calcium levels were higher in normal BMD group. On the other hand, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were significantly higher in normal bone mass postmenopausal women and men as compared to age-matched osteoporotic groups. Finally, leptin was significantly lower in men, after correcting these results for body mass index values. The remaining variables assessed had a similar distribution among the different studied groups. In our population, low serum levels of leptin and high serum levels of zinc, calcium, FSH, and LH were associated with a higher BMD.
Literatur
1.
Zurück zum Zitat Seeman E, Hopper JL, Bach LA, et al (1989) Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 320:554–558PubMedCrossRef Seeman E, Hopper JL, Bach LA, et al (1989) Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 320:554–558PubMedCrossRef
2.
Zurück zum Zitat Liel Y, Edwards J, Shary J, Spicer KM, Gordon L, Bell NH (1988) The effects of race and body habitus in bone mineral density of the radius, hip and spine, in premenopausal women. J Clin Endocrinol Metab 66:1247–1250PubMedCrossRef Liel Y, Edwards J, Shary J, Spicer KM, Gordon L, Bell NH (1988) The effects of race and body habitus in bone mineral density of the radius, hip and spine, in premenopausal women. J Clin Endocrinol Metab 66:1247–1250PubMedCrossRef
3.
Zurück zum Zitat Sambrook PN, Dequeker J, Rasp HH (1998) Osteoporosis. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, London Sambrook PN, Dequeker J, Rasp HH (1998) Osteoporosis. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, London
4.
Zurück zum Zitat Compston JE, Rosen CJ (1999) Physiopathology. In: Compston JE, Rosen CJ (eds) Osteoporosis, 2nd edn. Health, Oxford Compston JE, Rosen CJ (1999) Physiopathology. In: Compston JE, Rosen CJ (eds) Osteoporosis, 2nd edn. Health, Oxford
5.
Zurück zum Zitat Tremollieres FA, Pouilles JM, Ribot C (1993) Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 77:683–686PubMedCrossRef Tremollieres FA, Pouilles JM, Ribot C (1993) Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 77:683–686PubMedCrossRef
6.
Zurück zum Zitat Stewart A, Black AJ (2000) Bone mineral density in osteoarthritis. Curr Opin Rheumatol 12:464–467PubMedCrossRef Stewart A, Black AJ (2000) Bone mineral density in osteoarthritis. Curr Opin Rheumatol 12:464–467PubMedCrossRef
7.
Zurück zum Zitat Hegarty VM, May HM, Khaw KT (2000) Tea drinking and bone mineral density in older women. Am J Clin Nutr 71:1003–1007PubMed Hegarty VM, May HM, Khaw KT (2000) Tea drinking and bone mineral density in older women. Am J Clin Nutr 71:1003–1007PubMed
8.
Zurück zum Zitat Louis E, Franchimont D, Piron A, et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401–406PubMedCrossRef Louis E, Franchimont D, Piron A, et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401–406PubMedCrossRef
9.
Zurück zum Zitat Fonseca JE, Carvalho T, Cruz M, et al (2005) Polymorphism at position −308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 64:793–794PubMedCrossRef Fonseca JE, Carvalho T, Cruz M, et al (2005) Polymorphism at position −308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 64:793–794PubMedCrossRef
10.
Zurück zum Zitat Mourão AF, Cavaleiro J, Teles J, et al (2006) Tumor Necrosis Factor α – 308 GA/AA genotypes are associated with high inflammatory activity and high serum Tumor Necrosis Factor α in Juvenile Idiopathic Arthritis patients. Arthritis Rheum 54(9 suppl):S694 Mourão AF, Cavaleiro J, Teles J, et al (2006) Tumor Necrosis Factor α – 308 GA/AA genotypes are associated with high inflammatory activity and high serum Tumor Necrosis Factor α in Juvenile Idiopathic Arthritis patients. Arthritis Rheum 54(9 suppl):S694
11.
Zurück zum Zitat Fonseca JE, Cavaleiro J, Teles J, et al (2007) Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumour necrosis factor alpha gene promoter. Arthritis Res Ther 9(2):R37, 2007 Apr 4PubMedCrossRef Fonseca JE, Cavaleiro J, Teles J, et al (2007) Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumour necrosis factor alpha gene promoter. Arthritis Res Ther 9(2):R37, 2007 Apr 4PubMedCrossRef
12.
Zurück zum Zitat Khanna D, Wu H, Park G, Western Consortium of Practicing Rheumatologists, et al (2006) Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 54:1105–1116PubMedCrossRef Khanna D, Wu H, Park G, Western Consortium of Practicing Rheumatologists, et al (2006) Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 54:1105–1116PubMedCrossRef
13.
Zurück zum Zitat Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93–S99PubMed Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93–S99PubMed
14.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum Mar 31:315–324CrossRef Arnett FC, Edworthy SM, Bloch DA, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum Mar 31:315–324CrossRef
15.
Zurück zum Zitat Canhão H, Fonseca JE, Queiroz MV (2004) [Questionnaire for osteoporosis risk factors identification]. Acta Reuma Port 29:63–69 Canhão H, Fonseca JE, Queiroz MV (2004) [Questionnaire for osteoporosis risk factors identification]. Acta Reuma Port 29:63–69
16.
Zurück zum Zitat Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650CrossRef Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650CrossRef
17.
Zurück zum Zitat Kanis JA, Melton LJ III, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRef Kanis JA, Melton LJ III, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRef
18.
Zurück zum Zitat Chen BH, Tsai JL, Tsai LY, Chao MC (1999) Comparison of serum copper, magnesium, zinc and calcium levels between G6PD deficient and normal Chinese adults. Kaohsiung J Med Sci 15:646–650PubMed Chen BH, Tsai JL, Tsai LY, Chao MC (1999) Comparison of serum copper, magnesium, zinc and calcium levels between G6PD deficient and normal Chinese adults. Kaohsiung J Med Sci 15:646–650PubMed
19.
Zurück zum Zitat Mataran Perez L, Gonzalez Dominguez J, Rodriguez Perez M, Rodrigo D, Abellan Perez M, Salvatierra Rios D (1992) Zinc and osteoporosis. An Med Interna 9:331–333PubMed Mataran Perez L, Gonzalez Dominguez J, Rodriguez Perez M, Rodrigo D, Abellan Perez M, Salvatierra Rios D (1992) Zinc and osteoporosis. An Med Interna 9:331–333PubMed
20.
Zurück zum Zitat Ibs KH, Rink L (2003) Zinc-Altered Immune Function. J Nutr 133(suppl):1452S–1456SPubMed Ibs KH, Rink L (2003) Zinc-Altered Immune Function. J Nutr 133(suppl):1452S–1456SPubMed
21.
Zurück zum Zitat Neldner KH, Hambidge KM (1975) Zinc therapy in acroderamtitis enteropathica. N Engl J Med 292:879–882PubMedCrossRef Neldner KH, Hambidge KM (1975) Zinc therapy in acroderamtitis enteropathica. N Engl J Med 292:879–882PubMedCrossRef
22.
Zurück zum Zitat Favier A, Favier M (1990) [Consequences des deficits en zinc durant la grossesse pour la mere et le nouveau ne]. Rev Fr Gynecol Obstet 85:13–27PubMed Favier A, Favier M (1990) [Consequences des deficits en zinc durant la grossesse pour la mere et le nouveau ne]. Rev Fr Gynecol Obstet 85:13–27PubMed
23.
Zurück zum Zitat Prasad AS, Bao B, Beck FW, Kucuk O, Sarkar FH (2004) Antioxidant effect of zinc in humans. Free Radic Biol Med 37:1182–1190PubMedCrossRef Prasad AS, Bao B, Beck FW, Kucuk O, Sarkar FH (2004) Antioxidant effect of zinc in humans. Free Radic Biol Med 37:1182–1190PubMedCrossRef
24.
Zurück zum Zitat Giwa OG, Anetor JI, Alonge TO, Agbedana EO (2004) Biochemical observations in Blount’s disease (infantile tibia vara). J Natl Med Assoc 96:1203–1207PubMed Giwa OG, Anetor JI, Alonge TO, Agbedana EO (2004) Biochemical observations in Blount’s disease (infantile tibia vara). J Natl Med Assoc 96:1203–1207PubMed
25.
Zurück zum Zitat Prasad AS (1998) Zinc in human health: an update. J Trace Elem Exp Med 11:63–87CrossRef Prasad AS (1998) Zinc in human health: an update. J Trace Elem Exp Med 11:63–87CrossRef
26.
Zurück zum Zitat Canhão H, Fonseca JE, Queiroz MV (2006) [Evaluation of diet habits and lifestyle in a Portuguese population—osteoporosis risk and protective factors]. Acta Reumatol Port 31:331–339PubMed Canhão H, Fonseca JE, Queiroz MV (2006) [Evaluation of diet habits and lifestyle in a Portuguese population—osteoporosis risk and protective factors]. Acta Reumatol Port 31:331–339PubMed
27.
Zurück zum Zitat Suresh M, Naidu DM (2006) Influence of years since menopause on bone mineral metabolism in South Indian women. Indian J Med Sci 60:190–198PubMedCrossRef Suresh M, Naidu DM (2006) Influence of years since menopause on bone mineral metabolism in South Indian women. Indian J Med Sci 60:190–198PubMedCrossRef
28.
Zurück zum Zitat Lamghari M, Tavares L, Camboa N, Barbosa MA (2006) Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. J Cell Biochem 98:1123–1129PubMedCrossRef Lamghari M, Tavares L, Camboa N, Barbosa MA (2006) Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. J Cell Biochem 98:1123–1129PubMedCrossRef
29.
Zurück zum Zitat Harada S, Rodan GA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349–355PubMedCrossRef Harada S, Rodan GA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349–355PubMedCrossRef
30.
Zurück zum Zitat Ducy P, Amling M, Takeda S, et al (2000) Leptin inhibits bone formation through a hypothalamic relay—a central control of bone mass. Cell 100:197–207PubMedCrossRef Ducy P, Amling M, Takeda S, et al (2000) Leptin inhibits bone formation through a hypothalamic relay—a central control of bone mass. Cell 100:197–207PubMedCrossRef
31.
Zurück zum Zitat Elefteriou F, Takeda S, Ebihara K, et al (2004) Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101:3258–3263PubMedCrossRef Elefteriou F, Takeda S, Ebihara K, et al (2004) Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101:3258–3263PubMedCrossRef
32.
Zurück zum Zitat Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 99:1078–1083PubMed Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 99:1078–1083PubMed
33.
Zurück zum Zitat Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122PubMed Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122PubMed
34.
Zurück zum Zitat Tavares V, Canhão H, Melo Gomes JA et al (2007) Portuguese Society of Rheumatology and Portuguese Society of Bone Mineral Diseases. [Guidelines for Osteoporosis Diagnosis and Management]. Acta Reuma Port 32:49–59 Tavares V, Canhão H, Melo Gomes JA et al (2007) Portuguese Society of Rheumatology and Portuguese Society of Bone Mineral Diseases. [Guidelines for Osteoporosis Diagnosis and Management]. Acta Reuma Port 32:49–59
35.
Zurück zum Zitat Ota N, Hunt SC, Nakajima T, et al (2000) Linkage of human tumor necrosis factor-alpha to human osteoporosis by sib pair analysis. Genes Immun 1:260–264PubMedCrossRef Ota N, Hunt SC, Nakajima T, et al (2000) Linkage of human tumor necrosis factor-alpha to human osteoporosis by sib pair analysis. Genes Immun 1:260–264PubMedCrossRef
36.
Zurück zum Zitat Ota N, Nakajima T, Ezura Y, et al (2002) Association of a single nucleotide variant in the human tumour necrosis factor alpha promoter region with decreased bone mineral density. Ann Hum Biol 29:550–558PubMedCrossRef Ota N, Nakajima T, Ezura Y, et al (2002) Association of a single nucleotide variant in the human tumour necrosis factor alpha promoter region with decreased bone mineral density. Ann Hum Biol 29:550–558PubMedCrossRef
37.
Zurück zum Zitat Furuta I, Kobayashi N, Fujino T, et al (2004) Bone mineral density of the lumbar spine is associated with TNF gene polymorphisms in early postmenopausal Japanese women. Calcif Tissue Int 74:509–515PubMedCrossRef Furuta I, Kobayashi N, Fujino T, et al (2004) Bone mineral density of the lumbar spine is associated with TNF gene polymorphisms in early postmenopausal Japanese women. Calcif Tissue Int 74:509–515PubMedCrossRef
38.
Zurück zum Zitat Chen HY, Chen WC, Hsu CM, Tsai FJ, Tsai CH (2005) Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol 122:73–78PubMedCrossRef Chen HY, Chen WC, Hsu CM, Tsai FJ, Tsai CH (2005) Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol 122:73–78PubMedCrossRef
39.
Zurück zum Zitat Moffett SP, Zmuda JI, Oakley TJ et al (2005) Tumor necrosis factor alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab 90:3491–3497PubMedCrossRef Moffett SP, Zmuda JI, Oakley TJ et al (2005) Tumor necrosis factor alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab 90:3491–3497PubMedCrossRef
Metadaten
Titel
Assessment of laboratory measurements and −308 TNFα gene promoter polymorphisms in normal bone mineral density
verfasst von
Helena Canhao
Joao Eurico Fonseca
Joana Caetano-Lopes
Carlota Saldanha
Mario Viana Queiroz
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 3/2008
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0706-y

Weitere Artikel der Ausgabe 3/2008

Clinical Rheumatology 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.